Galmed Pharmaceuticals Ltd.
EOCN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001595353
No open-market purchases or sales by Galmed Pharmaceuticals Ltd. insiders were filed in the last 90 days; 14 institutions reported holding it in 13F filings for Q2 2026, worth $85.9K in total; no superinvestor holds it.
Q2 2026 vs. Q1 2026
How the institutions holding Galmed Pharmaceuticals Ltd. changed between Q1 2026 and Q2 2026.
All holders in Q2 2026All holders in Q1 2026
| Measure | Q1 2026 | Q2 2026 | Change |
|---|---|---|---|
| Holders | 16 | 14 | −2 |
| Shares | 145.8K | 155.7K | +9.95K (+6.8%) |
| Value | $71.2K | $85.9K | +$14.7K (+20.7%) |
New holders (2)
Institutions that held Galmed Pharmaceuticals Ltd. at the end of Q2 2026 but not at the end of Q1 2026.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| HRT Financial LP | 42,090 | $23.0K | 0.00% |
| Royal Bank of Canada | 550 | $0 | 0.00% |
Sold out (4)
Institutions that held Galmed Pharmaceuticals Ltd. at the end of Q1 2026 and filed for Q2 2026 without it.
| Institution | Shares, Q1 2026 | Value, Q1 2026 |
|---|---|---|
| Two Sigma Investments, LP | 80,177 | $39.3K |
| Jane Street Group, LLC | 16,445 | $8.06K |
| BNP Paribas Arbitrage, SA | 600 | $294 |
| Dogwood Wealth Management LLC | 1 | $0 |